Monday, October 17, 2016
- More than 38 presentations to feature SMRT® Sequencing, including data from the new Sequel™ System
- New Sequel System chemistry to be released that dramatically reduces input DNA requirements
The company will also introduce a new Sequel System chemistry release (1.2.1) that enables loading of sequencing libraries with average insert size of 20-30 kb onto Sequel SMRT Cells with a ~50-fold reduction of DNA input requirement compared to previous Sequel chemistry. Internal results using the new Sequel System chemistry, which have been replicated at several beta sites, have shown mapped read-length N50s of > 16 kb and output of > 5 Gb per Sequel SMRT Cell. Additional details will be discussed during the company’s ASHG workshop (more details on the event below), and commercial availability is expected starting
Highlights from the scientific presentations featuring PacBio® sequencing include:
- Targeted long-read sequencing of genomic disorders to identify complex structural variation events
- Concurrent invited session 1 on Wednesday, 10/19 at
12 p.m. : “Mechanisms of Rearrangements in Genomic Disorders: From the Bedside to the Bench Side,” with speakerChristine R. Beck from theBaylor College of Medicine - Platform presentation #164 on Thursday, 10/20 at
12:45 p.m. : “Combined Next Generation Sequencing Techniques Untangle the
Genomic Structure of Complex Nonrecurrent Deletions in Subjects with Smith-Magenis Syndrome and Reveal a Strong Bias to Paternally Deleted Chromosomes,” with speakerClaudia Fonseca fromBaylor College of Medicine
- Concurrent invited session 1 on Wednesday, 10/19 at
- Integrative Genomics Viewer (IGV) improvements for visualization of structural variants and phased allele haplotypes in long contiguous PacBio single-molecule reads
- Interactive invited workshop on Thursday, 10/20 at
7:15 a.m. : “Introduction to the Integrative Genomics Viewer (IGV)” (speaker?)
- Interactive invited workshop on Thursday, 10/20 at
- Use of the Iso-Seq™ method for annotation of novel genes and alternatively spliced gene isoforms in clinically significant genes
- Platform presentation on Saturday, 10/22
at9:45 a.m. : “Improving gene annotation to facilitate identification of missing variants of clinical significance,” with speakerAdam Frankish of theWellcome Trust Sanger Institute
- Platform presentation on Saturday, 10/22
- Haplotype phasing of full-length genes and gene transcripts using long-read sequencing of long-range PCR amplicons
- Poster #698: “Haplotype Phasing of Key Cardiac Disease Genes at Genome and Transcriptome Levels Using Long-read Sequencing Technologies,” by
Alexandra Dainis ofStanford University
- Poster #698: “Haplotype Phasing of Key Cardiac Disease Genes at Genome and Transcriptome Levels Using Long-read Sequencing Technologies,” by
- Novel targeted sequencing methods for improved resolution of structural variants in disease-causing genes
- Poster #3324: “Single Molecule, Real-Time
(SMRT) Sequencing of Expanded Spinocerebellar Ataxia Type 10 (SCA10) Pentanucleotide Repeat Alleles Directly from Genomic DNA,” byTetsuo Ashizawa of theHouston Methodist Research Institute - Poster #1690: “SMRT Sequencing of STR Expansions in SCA31 Brain Disease,” by
Wei Qu of theUniversity of Tokyo
- Poster #3324: “Single Molecule, Real-Time
- Cost-effective methods to replace
Sanger sequencing for validation of variants
- Poster #996: “SMRTer Confirmation”: Scalable Clinical Read-through Variant Confirmation Using the Pacific Biosciences SMRT® Sequencing Platform,” by
Sarah McCalmon from Invitae Corporation
- Poster #996: “SMRTer Confirmation”: Scalable Clinical Read-through Variant Confirmation Using the Pacific Biosciences SMRT® Sequencing Platform,” by
PacBio
will also be hosting a workshop on Thursday, 10/20 at
in targeted sequencing studies. Melissa Laird Smith’s workshop talk will feature Sequel data generated at the
The workshop will be hosted by PacBio Chief Scientific Officer,
dataset will be available to view using a new version of the Integrative Genomics Viewer, with improved support for PacBio SMRT Sequencing data, at the PacBio booth on the exhibit hall floor (#718). Attendees interested in reserving a seat at the workshop, or scientists not attending the meeting who wish to watch the live stream online, can register here.
“Last year at this time we launched our new Sequel System, and this year scientists will hear some of the first presentations about data and results obtained using this improved and enhanced SMRT Sequencing platform,” said
and colleagues at the industry’s most important annual human genetics meeting, though we are deeply saddened that one of the most important contributors to the field will not be joining us. Dr.
About Pacific Biosciences
improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses, quality or performance of, or benefits of using, products or technologies, updates or improvements of the company’s products, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and
could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Contacts Media:Nicole Litchfield 415.793.6468 nicole@bioscribe.com Investors:Trevin Rard 650.521.8450 ir@pacificbiosciences.com
Source:
News Provided by Acquire Media